NASDAQ:RTTR - Ritter Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$3.39 +0.02 (+0.59 %)
(As of 05/27/2018 04:00 PM ET)
Previous Close$3.39
Today's Range$3.31 - $3.44
52-Week Range$1.80 - $8.00
Volume36,557 shs
Average Volume109,364 shs
Market Capitalization$17.02 million
P/E Ratio-0.68
Dividend YieldN/A
Beta0.57

About Ritter Pharmaceuticals (NASDAQ:RTTR)

Ritter Pharmaceuticals logoRitter Pharmaceuticals, Inc., a specialty pharmaceutical company, develops novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b/3 clinical trial for the reduction of symptoms associated with lactose intolerance. The company's product, RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon, thereby adapting the gut microbiome to assist in digesting the lactose that reaches the large intestine. It is also exploring the functionality and discovering the therapeutic potential gut microbiome changes may have on treating/preventing various conditions, including gastrointestinal diseases, immuno-oncology, metabolic, and liver disease. The company was formerly known as Ritter Natural Sciences, LLC and changed its name to Ritter Pharmaceuticals, Inc. in September 2008. Ritter Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Los Angeles, California.

Receive RTTR News and Ratings via Email

Sign-up to receive the latest news and ratings for RTTR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RTTR
CUSIPN/A
Phone310-203-1000

Debt

Debt-to-Equity RatioN/A
Current Ratio23.86
Quick Ratio23.86

Price-To-Earnings

Trailing P/E Ratio-0.68
Forward P/E Ratio-1.21
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.67 per share
Price / Book1.27

Profitability

EPS (Most Recent Fiscal Year)($5.00)
Net Income$-7,860,000.00
Net MarginsN/A
Return on Equity-136.12%
Return on Assets-85.45%

Miscellaneous

Employees9
Outstanding Shares5,020,000

Ritter Pharmaceuticals (NASDAQ:RTTR) Frequently Asked Questions

What is Ritter Pharmaceuticals' stock symbol?

Ritter Pharmaceuticals trades on the NASDAQ under the ticker symbol "RTTR."

When did Ritter Pharmaceuticals' stock split? How did Ritter Pharmaceuticals' stock split work?

Shares of Ritter Pharmaceuticals reverse split on the morning of Friday, March 23rd 2018. The 1-10 reverse split was announced on Thursday, March 22nd 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, March 22nd 2018. An investor that had 100 shares of Ritter Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

How were Ritter Pharmaceuticals' earnings last quarter?

Ritter Pharmaceuticals (NASDAQ:RTTR) released its quarterly earnings results on Tuesday, May, 15th. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by $0.01. View Ritter Pharmaceuticals' Earnings History.

What price target have analysts set for RTTR?

4 brokerages have issued 12-month price targets for Ritter Pharmaceuticals' stock. Their forecasts range from $15.00 to $20.00. On average, they expect Ritter Pharmaceuticals' stock price to reach $16.6667 in the next twelve months. View Analyst Ratings for Ritter Pharmaceuticals.

Who are some of Ritter Pharmaceuticals' key competitors?

Who are Ritter Pharmaceuticals' key executives?

Ritter Pharmaceuticals' management team includes the folowing people:
  • Mr. Ira E. Ritter, Co-Founder, Exec. Chairman & Chief Strategic Officer (Age 69)
  • Mr. Michael D. Step, CEO & Director (Age 58)
  • Mr. Andrew J. Ritter, Co-Founder, Pres, Corp. Sec. & Director (Age 35)
  • Mr. Jeffrey Benjamin, Principal Financial & Accounting Officer (Age 53)
  • Dr. Diane J. Plotkin Ph.D., VP of Clinical Devel.

When did Ritter Pharmaceuticals IPO?

(RTTR) raised $20 million in an initial public offering on Wednesday, June 24th 2015. The company issued 4,000,000 shares at a price of $5.00 per share. Aegis Capital Corp and Chardan Capital Markets acted as the underwriters for the IPO and Barrington Research was co-manager.

Has Ritter Pharmaceuticals been receiving favorable news coverage?

Press coverage about RTTR stock has trended somewhat positive this week, Accern reports. The research group ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Ritter Pharmaceuticals earned a media sentiment score of 0.17 on Accern's scale. They also assigned media stories about the biotechnology company an impact score of 44.90 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

How do I buy shares of Ritter Pharmaceuticals?

Shares of RTTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ritter Pharmaceuticals' stock price today?

One share of RTTR stock can currently be purchased for approximately $3.39.

How big of a company is Ritter Pharmaceuticals?

Ritter Pharmaceuticals has a market capitalization of $17.02 million. The biotechnology company earns $-7,860,000.00 in net income (profit) each year or ($5.00) on an earnings per share basis. Ritter Pharmaceuticals employs 9 workers across the globe.

How can I contact Ritter Pharmaceuticals?

Ritter Pharmaceuticals' mailing address is 1880 CENTURY PARK EAST SUITE 1000, LOS ANGELES CA, 90067. The biotechnology company can be reached via phone at 310-203-1000 or via email at [email protected]


MarketBeat Community Rating for Ritter Pharmaceuticals (RTTR)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  170 (Vote Outperform)
Underperform Votes:  139 (Vote Underperform)
Total Votes:  309
MarketBeat's community ratings are surveys of what our community members think about Ritter Pharmaceuticals and other stocks. Vote "Outperform" if you believe RTTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RTTR will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Ritter Pharmaceuticals (NASDAQ:RTTR) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Ritter Pharmaceuticals in the last 12 months. Their average twelve-month price target is $16.6667, suggesting that the stock has a possible upside of 391.64%. The high price target for RTTR is $20.00 and the low price target for RTTR is $15.00. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.752.752.802.83
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $16.6667$16.6667$25.00$34.00
Price Target Upside: 391.64% upside363.99% upside595.99% upside846.55% upside

Ritter Pharmaceuticals (NASDAQ:RTTR) Consensus Price Target History

Price Target History for Ritter Pharmaceuticals (NASDAQ:RTTR)

Ritter Pharmaceuticals (NASDAQ:RTTR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/23/2017Roth CapitalSet Price TargetBuy$20.00N/AView Rating Details
10/23/2017HC WainwrightLower Price TargetBuy ➝ Buy$70.00 ➝ $15.00N/AView Rating Details
8/8/2017Chardan CapitalLower Price TargetBuy ➝ Buy$35.00 ➝ $15.00MediumView Rating Details
8/4/2017Maxim GroupReiterated RatingHoldLowView Rating Details
3/7/2017AegisReiterated RatingBuyMediumView Rating Details
1/4/2017Rodman & RenshawInitiated CoverageBuy$70.00N/AView Rating Details
(Data available from 5/27/2016 forward)

Earnings

Ritter Pharmaceuticals (NASDAQ:RTTR) Earnings History and Estimates Chart

Earnings by Quarter for Ritter Pharmaceuticals (NASDAQ:RTTR)

Ritter Pharmaceuticals (NASDAQ:RTTR) Earnings Estimates

Current Year EPS Consensus Estimate: $-2.8 EPS
Next Year EPS Consensus Estimate: $-1.75 EPS

Ritter Pharmaceuticals (NASDAQ RTTR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/15/2018Q1 2018($0.40)($0.41)ViewN/AView Earnings Details
3/19/2018Q4 2017($0.50)($1.10)ViewN/AView Earnings Details
10/31/2017Q3 2017($1.43)($1.40)ViewN/AView Earnings Details
8/7/2017Q2 2017($1.45)($1.40)ViewN/AView Earnings Details
5/9/2017Q1 2017($3.80)($1.40)ViewN/AView Earnings Details
2/27/2017Q4 2016($3.46)($7.43)ViewN/AView Earnings Details
11/7/2016Q3 2016($5.00)($4.10)ViewN/AView Earnings Details
8/8/2016Q216($3.40)($4.80)ViewN/AView Earnings Details
5/9/2016($3.20)($3.60)ViewN/AView Earnings Details
3/21/2016Q4($3.40)($2.70)ViewN/AView Earnings Details
11/17/2015Q315($4.00)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Ritter Pharmaceuticals (NASDAQ:RTTR) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Ritter Pharmaceuticals (NASDAQ RTTR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 21.60%
Institutional Ownership Percentage: 19.80%
Insider Trading History for Ritter Pharmaceuticals (NASDAQ:RTTR)
Insider Trading History for Ritter Pharmaceuticals (NASDAQ:RTTR)

Ritter Pharmaceuticals (NASDAQ RTTR) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/18/2017Matthew W FoehrDirectorBuy18,000$0.62$11,160.0035,000View SEC Filing  
5/11/2017Michael D StepCEOBuy13,000$0.62$8,060.00View SEC Filing  
2/27/2017Michael D StepCEOBuy10,000$2.65$26,500.00View SEC Filing  
2/22/2016Andrew J RitterMajor ShareholderBuy6,250$1.60$10,000.006,250View SEC Filing  
1/8/2016Matthew W FoehrDirectorBuy13,000$1.64$21,320.0017,000View SEC Filing  
1/7/2016Michael D StepCEOBuy27,000$1.48$39,960.0027,000View SEC Filing  
6/24/2015Gerald T ProehlDirectorBuy50,000$5.00$250,000.00View SEC Filing  
6/24/2015Javelin Venture Partners, L.P.Major ShareholderBuy800,000$5.00$4,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Ritter Pharmaceuticals (NASDAQ RTTR) News Headlines

Source:
DateHeadline
Ritter Pharmaceuticals to Present Two Posters at Digestive Disease Week 2018 Highlighting Treatment Data of RP ...Ritter Pharmaceuticals to Present Two Posters at Digestive Disease Week 2018 Highlighting Treatment Data of RP ...
globenewswire.com - May 24 at 4:10 PM
Ritter Pharmaceuticals to Present Two Posters at Digestive Disease Week 2018 Highlighting Treatment Data of RP-G28 for Lactose IntoleranceRitter Pharmaceuticals to Present Two Posters at Digestive Disease Week 2018 Highlighting Treatment Data of RP-G28 for Lactose Intolerance
finance.yahoo.com - May 22 at 9:46 AM
Ritter Pharmaceuticals (RTTR) Issues  Earnings Results, Misses Estimates By $0.01 EPSRitter Pharmaceuticals (RTTR) Issues Earnings Results, Misses Estimates By $0.01 EPS
www.americanbankingnews.com - May 16 at 10:52 AM
Ritter Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business UpdatesRitter Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Updates
finance.yahoo.com - May 16 at 10:37 AM
Ritter Pharmaceuticals (RTTR) Receives Average Recommendation of "Buy" from BrokeragesRitter Pharmaceuticals (RTTR) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 13 at 7:52 PM
Ritter Pharmaceuticals (RTTR) Expected to Post Earnings of -$0.40 Per ShareRitter Pharmaceuticals (RTTR) Expected to Post Earnings of -$0.40 Per Share
www.americanbankingnews.com - May 11 at 11:24 AM
Ritter Pharmaceuticals (RTTR) Upgraded to Buy by Zacks Investment ResearchRitter Pharmaceuticals (RTTR) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - May 8 at 11:02 AM
Ritter Pharmaceuticals (RTTR) Upgraded by ValuEngine to "Hold"Ritter Pharmaceuticals (RTTR) Upgraded by ValuEngine to "Hold"
www.americanbankingnews.com - May 2 at 6:30 PM
Ritter Pharmaceuticals Inc (RTTR) Expected to Post Earnings of -$0.40 Per ShareRitter Pharmaceuticals Inc (RTTR) Expected to Post Earnings of -$0.40 Per Share
www.americanbankingnews.com - April 23 at 11:10 PM
Ritter Pharmaceuticals Inc (RTTR) Given Consensus Recommendation of "Hold" by AnalystsRitter Pharmaceuticals Inc (RTTR) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - April 18 at 7:24 PM
Ritter Pharmaceuticals (RTTR) Upgraded by Zacks Investment Research to "Buy"Ritter Pharmaceuticals (RTTR) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - April 11 at 5:00 PM
Ritter Pharmaceuticals (RTTR) Stock Rating Upgraded by Zacks Investment ResearchRitter Pharmaceuticals (RTTR) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 8 at 5:55 PM
Ritter Pharmaceuticals (RTTR) Lifted to Buy at Zacks Investment ResearchRitter Pharmaceuticals (RTTR) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - April 8 at 11:33 AM
-$0.40 EPS Expected for Ritter Pharmaceuticals Inc (RTTR) This Quarter-$0.40 EPS Expected for Ritter Pharmaceuticals Inc (RTTR) This Quarter
www.americanbankingnews.com - April 6 at 11:20 PM
Ritter Pharmaceuticals (RTTR) Upgraded to "Buy" at Zacks Investment ResearchRitter Pharmaceuticals (RTTR) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - April 4 at 10:25 PM
Ritter Pharmaceuticals Inc (RTTR) Receives Average Rating of "Hold" from AnalystsRitter Pharmaceuticals Inc (RTTR) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - March 24 at 7:33 PM
Ritter Pharmaceuticals (RTTR) Upgraded to "Hold" by Zacks Investment ResearchRitter Pharmaceuticals (RTTR) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - March 23 at 6:49 PM
Ritter Pharma (RTTR) Reports 1-for-10 Reverse Share Split - StreetInsider.comRitter Pharma (RTTR) Reports 1-for-10 Reverse Share Split - StreetInsider.com
www.streetinsider.com - March 22 at 4:13 PM
Ritter Pharmaceuticals Announces 1-for-10 Reverse Stock Split - GlobeNewswire (press release)Ritter Pharmaceuticals Announces 1-for-10 Reverse Stock Split - GlobeNewswire (press release)
www.globenewswire.com - March 22 at 4:13 PM
Ritter Pharmaceuticals Announces 1-for-10 Reverse Stock SplitRitter Pharmaceuticals Announces 1-for-10 Reverse Stock Split
finance.yahoo.com - March 22 at 4:13 PM
Ritter Pharmaceuticals Reports Fourth Quarter and Full Year 2017 ... - GlobeNewswire (press release)Ritter Pharmaceuticals Reports Fourth Quarter and Full Year 2017 ... - GlobeNewswire (press release)
globenewswire.com - March 19 at 4:11 PM
Ritter Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business UpdateRitter Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
finance.yahoo.com - March 19 at 10:38 AM
Ritter Pharma (RTTR) Announces Microbiome Data from Phase 2b Study of RP-G28 Promotes Beneficial Adaptation of Gut MicrobiomeRitter Pharma (RTTR) Announces Microbiome Data from Phase 2b Study of RP-G28 Promotes Beneficial Adaptation of Gut Microbiome
www.streetinsider.com - March 14 at 4:07 PM
Ritter Pharmaceuticals Reports Microbiome Data from Phase 2b ... - GlobeNewswire (press release)Ritter Pharmaceuticals Reports Microbiome Data from Phase 2b ... - GlobeNewswire (press release)
globenewswire.com - March 12 at 4:01 PM
Ritter Pharmaceuticals Reports Microbiome Data from Phase 2b Study of RP-G28 Promotes Beneficial Adaptation of the Gut MicrobiomeRitter Pharmaceuticals Reports Microbiome Data from Phase 2b Study of RP-G28 Promotes Beneficial Adaptation of the Gut Microbiome
finance.yahoo.com - March 12 at 4:01 PM
Ritter Pharmaceuticals (RTTR) Downgraded by Zacks Investment Research to "Sell"Ritter Pharmaceuticals (RTTR) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - March 8 at 4:17 PM
HC Wainwright Analysts Give Ritter Pharmaceuticals (RTTR) a $15.00 Price TargetHC Wainwright Analysts Give Ritter Pharmaceuticals (RTTR) a $15.00 Price Target
www.americanbankingnews.com - March 5 at 2:58 PM
Ritter Pharmaceuticals Inc (RTTR) Expected to Post Earnings of -$0.04 Per ShareRitter Pharmaceuticals Inc (RTTR) Expected to Post Earnings of -$0.04 Per Share
www.americanbankingnews.com - March 3 at 7:20 PM
Ritter Pharma (RTTR) Approves 1-for-10 Reverse Stock SplitRitter Pharma (RTTR) Approves 1-for-10 Reverse Stock Split
www.streetinsider.com - March 2 at 10:14 AM
Ritter Pharmaceuticals, Inc.’s Board Approves 1-for-10 Reverse Stock SplitRitter Pharmaceuticals, Inc.’s Board Approves 1-for-10 Reverse Stock Split
finance.yahoo.com - March 2 at 10:14 AM
Ritter Pharmaceuticals Inc (RTTR) Receives Average Recommendation of "Hold" from AnalystsRitter Pharmaceuticals Inc (RTTR) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - February 27 at 7:30 PM
Ritter Pharmaceuticals Appoints Distinguished Gastroenterologist, William Chey, MD, to Medical Advisory Board - GlobeNewswire (press release)Ritter Pharmaceuticals Appoints Distinguished Gastroenterologist, William Chey, MD, to Medical Advisory Board - GlobeNewswire (press release)
globenewswire.com - February 22 at 4:06 PM
Analyzing Ritter Pharmaceuticals (RTTR) and Selecta Biosciences (SELB)Analyzing Ritter Pharmaceuticals (RTTR) and Selecta Biosciences (SELB)
www.americanbankingnews.com - February 22 at 3:48 PM
Zacks: Analysts Anticipate Ritter Pharmaceuticals Inc (RTTR) Will Announce Earnings of -$0.05 Per ShareZacks: Analysts Anticipate Ritter Pharmaceuticals Inc (RTTR) Will Announce Earnings of -$0.05 Per Share
www.americanbankingnews.com - February 15 at 3:16 AM
Head to Head Survey: Tocagen (TOCA) & Ritter Pharmaceuticals (RTTR)Head to Head Survey: Tocagen (TOCA) & Ritter Pharmaceuticals (RTTR)
www.americanbankingnews.com - February 4 at 11:08 PM
Ritter Pharmaceuticals (RTTR) Upgraded by ValuEngine to SellRitter Pharmaceuticals (RTTR) Upgraded by ValuEngine to Sell
www.americanbankingnews.com - February 4 at 2:52 PM
Ritter Pharmaceuticals Inc (RTTR) Given Consensus Rating of "Hold" by BrokeragesRitter Pharmaceuticals Inc (RTTR) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - February 2 at 7:22 PM
Ritter Pharmaceuticals Appoints Diane J. Plotkin as Vice President ... - GlobeNewswire (press release)Ritter Pharmaceuticals Appoints Diane J. Plotkin as Vice President ... - GlobeNewswire (press release)
globenewswire.com - January 29 at 3:20 PM
Ritter Pharmaceuticals Appoints Diane J. Plotkin as Vice President of Clinical Development, Ahead of the Launch of its Phase 3 Clinical TrialRitter Pharmaceuticals Appoints Diane J. Plotkin as Vice President of Clinical Development, Ahead of the Launch of its Phase 3 Clinical Trial
finance.yahoo.com - January 29 at 3:20 PM
Critical Contrast: Ritter Pharmaceuticals (RTTR) & The CompetitionCritical Contrast: Ritter Pharmaceuticals (RTTR) & The Competition
www.americanbankingnews.com - January 13 at 7:52 AM
Reviewing Ritter Pharmaceuticals (RTTR) & Its CompetitorsReviewing Ritter Pharmaceuticals (RTTR) & Its Competitors
www.americanbankingnews.com - January 11 at 3:34 PM
Ritter Pharmaceuticals, Inc. (RTTR) Given Average Rating of "Buy" by BrokeragesRitter Pharmaceuticals, Inc. (RTTR) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - January 8 at 10:02 PM
Ritter Pharmaceuticals Inc (NASDAQ:RTTR): Earnings To Drop Next Year, Is It A Long-Term Trend?Ritter Pharmaceuticals Inc (NASDAQ:RTTR): Earnings To Drop Next Year, Is It A Long-Term Trend?
finance.yahoo.com - January 2 at 9:09 PM
Ritter Pharmaceuticals (RTTR) versus The Competition Head-To-Head ReviewRitter Pharmaceuticals (RTTR) versus The Competition Head-To-Head Review
www.americanbankingnews.com - January 1 at 11:32 PM
Analyzing Ritter Pharmaceuticals (RTTR) and Its RivalsAnalyzing Ritter Pharmaceuticals (RTTR) and Its Rivals
www.americanbankingnews.com - December 30 at 1:26 AM
 Analysts Expect Ritter Pharmaceuticals, Inc. (RTTR) to Announce -$0.05 Earnings Per Share Analysts Expect Ritter Pharmaceuticals, Inc. (RTTR) to Announce -$0.05 Earnings Per Share
www.americanbankingnews.com - December 26 at 6:18 PM
Ritter Pharmaceuticals (RTTR) Downgraded by Zacks Investment ResearchRitter Pharmaceuticals (RTTR) Downgraded by Zacks Investment Research
www.americanbankingnews.com - December 26 at 7:36 AM
Try Rising P/E Investing With 5 Top-Ranked Stocks - NasdaqTry Rising P/E Investing With 5 Top-Ranked Stocks - Nasdaq
www.nasdaq.com - December 19 at 3:45 PM
Ritter Pharmaceuticals, Inc. (RTTR) Given Average Recommendation of "Buy" by AnalystsRitter Pharmaceuticals, Inc. (RTTR) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - December 14 at 11:58 PM
Who Are Ritter Pharmaceuticals Inc’s (RTTR) Major Shareholders?Who Are Ritter Pharmaceuticals Inc’s (RTTR) Major Shareholders?
finance.yahoo.com - December 9 at 11:12 AM

SEC Filings

Ritter Pharmaceuticals (NASDAQ:RTTR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Ritter Pharmaceuticals (NASDAQ:RTTR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Ritter Pharmaceuticals (NASDAQ RTTR) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.